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Abstract
Background: Anxiety and depression are prevalent among cardiac rehabilitation patients but pharmacological and
psychological treatments have limited effectiveness in this group. Furthermore, psychological interventions have
not been systematically integrated into cardiac rehabilitation services despite being a strategic priority for the UK
National Health Service. A promising new treatment, metacognitive therapy, may be well-suited to the needs of
cardiac rehabilitation patients and has the potential to improve outcomes. It is based on the metacognitive model,
which proposes that a thinking style dominated by rumination, worry and threat monitoring maintains emotional
distress. Metacognitive therapy is highly effective at reducing this thinking style and alleviating anxiety and
depression in mental health settings. This trial aims to evaluate the effectiveness and cost-effectiveness of
group-based metacognitive therapy for cardiac rehabilitation patients with elevated anxiety and/or depressive
symptoms.
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Methods/Design: The PATHWAY Group-MCT trial is a multicentre, two-arm, single-blind, randomised controlled trial
comparing the clinical- and cost-effectiveness of group-based metacognitive therapy plus usual cardiac rehabilitation
to usual cardiac rehabilitation alone. Cardiac rehabilitation patients (target sample n = 332) with elevated anxiety and/
or depressive symptoms will be recruited across five UK National Health Service Trusts. Participants randomised to the
intervention arm will receive six weekly sessions of group-based metacognitive therapy delivered by either cardiac
rehabilitation professionals or research nurses. The intervention and control groups will both be offered the usual
cardiac rehabilitation programme within their Trust. The primary outcome is severity of anxiety and depressive
symptoms at 4-month follow-up measured by the Hospital Anxiety and Depression Scale total score. Secondary
outcomes are severity of anxiety/depression at 12-month follow-up, health-related quality of life, severity of post-traumatic
stress symptoms and strength of metacognitive beliefs at 4- and 12-month follow-up. Qualitative interviews will help to
develop an account of barriers and enablers to the effectiveness of the intervention.
Discussion: This trial will evaluate the effectiveness and cost-effectiveness of group-based metacognitive therapy
in alleviating anxiety and depression in cardiac rehabilitation patients. The therapy, if effective, offers the potential
to improve psychological wellbeing and quality of life in this large group of patients.
Trial registration: UK Clinical Trials Gateway, ISRCTN74643496, Registered on 8 April 2015.
Keywords: Metacognitive therapy, rumination, worry, anxiety, depression, cardiac rehabilitation, group therapy,
psychological intervention, heart disease,
Background
Cardiac rehabilitation (CR) services aim to improve heart
disease patients’ health and quality of life, and reduce the
risk of recurrent cardiac events [1]. Approximately 96,000
patients attend CR annually in the UK across 324 CR pro-
grammes at an annual total cost of approximately £42 mil-
lion [1–3]. Emotional distress is highly prevalent among
CR patients. National CR data demonstrate that 37% of
patients starting CR have clinically significant levels of anx-
iety and/or depressive symptoms and 40% of these patients
have mixed anxiety and depression, which further increases
the burden of distress [1]. Post-traumatic stress disorder is
also common with 12% of acute coronary syndrome pa-
tients developing this disorder following hospitalisation
with a myocardial infarction or unstable angina [4].
Distressed patients are at greater risk of death and fur-
ther cardiac events [5, 6], have a poorer quality of life
[7], and use more healthcare resources [8–10], leading
to greater National Health Service (NHS) costs [11]. Dis-
tress can also delay or prevent patients returning to
work [12]. Therefore, emotional distress is a significant
problem for CR patients, the NHS and society.
In 2010, the UK Department of Health implemented
the CR commissioning pack to improve CR services.
The pack details a comprehensive service specification
with a seven-stage care pathway from patient presenta-
tion, referral and assessment through to long-term
maintenance [13]. Although psychological assessment
and support are advocated throughout this pathway and
in other key NHS policies [14–16], CR patients with
anxiety and depression are not being effectively treated;
indeed, only 19% of group CR programmes include a
psychological component, 2% of patients receive individ-
ual psychological interventions, and no manualised psy-
chological interventions for depression and/or anxiety
are available for general use [1]. Following CR, 24% of
patients still have elevated anxiety and 13% have depres-
sive symptoms, with rates rising to 26% and 16%,
respectively, 9 months later [1]. Pharmacological and
psychological treatments that have been evaluated in
these patients have limited effects on psychological out-
comes [17–21] and health-related quality of life
(HRQoL) [22], and no improvement in cardiovascular
outcomes [17, 21]. Given the limitations of existing
treatments and CR services, it is imperative that effective
psychological interventions for depression and anxiety
are developed and integrated into the CR pathway to im-
prove clinical outcomes, patient quality of life and cost-
effectiveness.
An evidence-based model from mental health – the
metacognitive model [23, 24] – provides the basis for a
potentially effective and practicable treatment for
depression and anxiety in CR patients. In this model, a
maladaptive style of thinking and coping maintains
symptoms across a wide range of emotional problems,
including depression and anxiety. The model comprises
three processes, namely (1) repetitive, difficult-to-control
thinking (worry and/or rumination), (2) focusing atten-
tion on potential threats (e.g. thoughts, physical sensa-
tions, emotions), and (3) maladaptive attempts to
control unwanted thoughts (e.g. avoidance, reassurance-
seeking, alcohol/substance misuse). These metacognitive
processes are maintained by two types of underlying
metacognitive beliefs, specifically (1) positive beliefs
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about the usefulness of worry, rumination, threat moni-
toring and other coping strategies (e.g. “Worrying about
my health will help prevent future illness”, “Constantly
focusing on my body helps to keep me safe”) and (2)
negative beliefs about the uncontrollability of thoughts
and their damaging effects on the body and mind (e.g. “I
cannot control my rumination”, “Worry will damage my
health”). The metacognitive model is transdiagnostic,
wherein a small number of processes and beliefs main-
tain all forms of emotional distress. Consistent with this
model, the same processes and beliefs are associated
with depression and anxiety in patients with a diverse
range of physical health conditions, including heart
disease [25–27].
Metacognitive therapy (MCT) modifies the pro-
cesses and beliefs that maintain distress using a range
of well-specified strategies and techniques (see [28]
for treatment manual). In mental health settings,
MCT for depression and anxiety disorders has been
evaluated in case series, as well as in uncontrolled
and controlled trials [29–35]. A recent meta-analysis
found MCT to be highly effective in treating depres-
sion and anxiety disorders. Large within-group effect
sizes were found across all trials from pre- to post-
treatment, with treatment gains maintained at follow-
up. In controlled trials, treatment gains following
MCT were large when compared to wait-list controls
and cognitive behaviour therapy [36].
There are three main reasons why MCT should
generalise to heart disease patients. First, as the
metacognitive model is transdiagnostic, disparate
symptoms of distress are addressed with the same
core treatment strategies; this makes it particularly
well-suited to heart disease patients who often have
mixed anxiety and depression. Second, the same
strategies are used to treat distress irrespective of
medical diagnosis, which makes it compatible with a
CR pathway design, where a range of heart disease
patients undertake the same CR programmes and
where 80% of patients have at least one other long-
term condition [1]. Finally, MCT focuses on modify-
ing cognitive processes (e.g. reducing worry duration)
rather than on cognitive content (e.g. reality testing
worries), which is the focus of cognitive behaviour
therapy. Therefore, it is amenable to working with
the realistic negative thoughts that often occur in
the context of heart disease, e.g. thoughts about the
possibility of recurrent cardiac events and the func-
tional limitations associated with poor physical
health.
Aims
The primary aim of the PATHWAY Group-MCT trial
is to evaluate the effectiveness of group-based MCT
(Group-MCT) plus usual CR compared to usual CR
alone in alleviating depression and/or anxiety in pa-
tients attending CR. Secondary aims are (1) to evalu-
ate the impact of Group-MCT on secondary
outcomes including post-traumatic stress, metacogni-
tive beliefs, and HRQoL, (2) to evaluate the cost-
effectiveness of Group-MCT, and (3) to obtain quali-
tative data to develop an account of the barriers and
enablers to the trial and to the intervention, and to
interpret evidence of effectiveness, including processes
that might underpin or compromise effectiveness or
explain its heterogeneity.
Methods/Design
Design
The PATHWAY Group-MCT trial is a multicentre,
two-arm, single-blind randomised controlled trial with
4- and 12-month follow-up comparing Group-MCT
plus usual CR with usual CR alone. Treatment as
usual (CR alone) is the chosen comparator because
there is currently no benchmark treatment for distress
in this group, existing treatments have limited effects
and this is the first test of group MCT in this patient
population. There are qualitative and economic evalu-
ations embedded within the trial. An overview of the
study process is provided in Fig. 1. A schedule of en-
rolment, interventions and assessments is provided in
Fig. 2 and a populated Standard Protocol Items: Rec-
ommendations for Intervention Trials (SPIRIT)
Checklist is provided in Additional file 1.
Trial population
The trial population are heart disease patients referred
to CR services at five NHS Trusts (University Hospital
of South Manchester NHS Foundation Trust, Central
Manchester University Hospitals NHS Foundation Trust,
East Cheshire NHS Trust, Stockport NHS Foundation
Trust, and Pennine Acute Hospitals NHS Trust).
Inclusion and exclusion criteria
Inclusion criteria:
1. Meets Department of Health and/or British
Association for Cardiac Prevention and Rehabilitation
CR eligibility criteria (acute coronary syndrome,
revascularisation, stable heart failure, stable angina,
implantation of cardioverter defibrillators/cardiac
resynchronisation devices, heart valve repair/
replacement, heart transplantation and ventricular
assist devices, adult congenital heart disease, other
atypical heart presentation).
2. A score of ≥ 8 on either the depression or anxiety
subscale of the Hospital Anxiety and Depression
Scale (HADS) [37]
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3. Aged 18 years or older
4. A competent level of English language skills
(able to read, understand and complete
questionnaires in English)
Exclusion criteria:
1. Cognitive impairment which precludes informed
consent or ability to participate
2. Life expectancy of less than 12 months
3. Acute suicidality
4. Active psychotic disorders
5. Current drug or alcohol abuse
6. Antidepressant or anxiolytic medications initiated in
the previous 8 weeks
7. Concurrent psychological intervention for
emotional distress
Recruitment and randomisation
Patients referred to the CR programme at each site
are routinely sent a National Audit of Cardiac Re-
habilitation assessment pack [1], which includes the
HADS [37]. Patients return the pack to the CR team
either at an initial assessment appointment or by
post. CR staff will screen the medical notes of
patients scoring eight or above on either the anxiety
or depression subscale of the HADS to determine if
they meet the trial inclusion and exclusion criteria.
Patients deemed eligible for the trial will be provided
with information about the study and a member of
Fig. 1 Trial flow diagram. CR cardiac rehabilitation, HADS Hospital Anxiety and Depression Scale, MCT metacognitive therapy
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the CR team will seek an expression of interest from
the patients.
Eligible and interested patients will be contacted by a
research assistant to arrange a suitable time and loca-
tion to meet prior to the patients starting the CR
programme (e.g. patients’ homes or NHS Trusts). Re-
search assistants will take written consent and adminis-
ter baseline questionnaires. After baseline assessments,
patients will be randomised via telephone link to the
Manchester Academic Health Science Centre Clinical
Trials Co-ordination Unit (MAHSC-CTU). Patients will
be allocated to trial arms in a 1:1 ratio via a minimisa-
tion algorithm (incorporating a random component) to
maximise balance between the two arms on sex, HADS
anxiety and depression scores [38], and hospital site. A
member of the research team will inform the partici-
pants of their allocation. Research assistants who are
collecting assessment data will be blind to treatment
allocation, as will the chief investigator (AW) and trial
statistician (DR).
Trial conditions
Usual CR
Participants in the control group will be offered the
usual CR programme at their site. The content and de-
livery of usual CR varies slightly across the participating
sites but all offer group-based programmes delivered in
either hospital or community settings. Group-based CR
runs weekly over 8–10 weeks and comprises a number
of components, including exercise, lifestyle and medical
risk factor management, and health behaviour change.
There is some limited psychosocial input (e.g. one-off
talks on stress management and relaxation techniques),
although one site offers a 4-week stress management
course as part of CR. Four of the sites also offer a
home-based programme to a small number of patients.
Home-based CR is tailored to each patient’s needs but
comprises similar components to group-based CR, in-
cluding an exercise programme that can be undertaken
at home or in the community as well as educational
components.
Group-MCT plus usual CR
The intervention group will receive group-based MCT
in addition to the usual CR at their site. The group inter-
vention will consist of six weekly sessions delivered by
two trained CR professionals (physiotherapists, nurses,
occupational therapists) or research nurses (depending
on site) over 1–1.5 h. The therapists will be guided by a
treatment manual to maximise treatment adherence.
The aim is to deliver the intervention to groups of
between three and ten participants, but this will vary de-
pending on recruitment and attrition rates. The aims of
the intervention are to help participants develop
Fig. 2 Schedule of enrolment, interventions and assessments. CR cardiac rehabilitation, Group-MCT group-based metacognitive therapy, HADS Hospital
Anxiety and Depression Scale, MCQ-30 Metacognitions Questionnaire 30, CAS-1 Cognitive Attentional Syndrome Scale, IES-R Impact of Event Scale-Revised,
EPQ Economic Patient Questionnaire
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knowledge that can facilitate control of worry, rumin-
ation and attention, and to modify the metacognitive be-
liefs that maintain these unhelpful patterns of thinking
[33]. There are eight major treatment techniques that
will be used across the six sessions, namely (1) formula-
tion, (2) socialisation, (3) the Spatial Attentional Control
Exercise, (4) detached mindfulness, (5) worry and
rumination postponement, (6) modifying metacognitive
beliefs about the uncontrollability and danger of worry
and rumination, (7) a ‘helpful behaviours prescription’,
and (8) individual treatment summaries. Sessions include
group discussions, experiential learning and homework
tasks that participants will be expected to complete be-
tween sessions. Participants will complete a set of ‘belief
thermometers’ at the start of each session, which meas-
ure three core metacognitive beliefs. The thermometers
will be used as a clinical tool for participants and thera-
pists to monitor change over the course of the interven-
tion. Treatment will be discontinued at any time for a
participant requesting it.
Therapist training and supervision
Therapists will initially receive 2 days of workshop train-
ing delivered by the developer of MCT (AW), which will
include didactic teaching, role plays, discussion and
studying of the treatment manual. This will be followed
by supervised practise in delivering the intervention to a
pilot group of volunteers and a further 1-day workshop,
which will address difficulties the therapists experienced
when delivering the intervention. Therapists’ delivery of
the intervention will be monitored by listening to audio-
recordings of Group-MCT sessions and they will receive
supervision as necessary throughout the trial.
Therapist competence and treatment adherence
Therapist competence will be evaluated by audio-
recording a random sample of 10% of treatment sessions
(where consent is provided by all participants in a group).
The sessions will be rated by independent MCT experts
using a competency checklist. Inter-rater Kappa coeffi-
cients for competency ratings will be reported. Adherence
to the manual will be assessed using an adherence check-
list completed by the therapists at each session.
Data collection
Participants will complete assessments at three time-points
– baseline (pre-CR), 4 months post-randomisation (4-month
follow-up) and 12 months post-randomisation (12-month
follow-up). Research assistants will administer baseline as-
sessments (see ‘Recruitment and randomisation’ above).
Participants will have a number of options for completing
the 4- and 12-month assessments either by post, or adminis-
tered by research assistants over the telephone or face-to-
face at participants’ homes or NHS trust. Participants will
receive shopping vouchers in return for completing the
assessments.
Measures
The following self-report outcome measures will be
completed at each assessment point:
Primary outcome measure
 The HADS [37] comprises 14 items measuring
symptoms of anxiety (7 items) and depression
(7 items). Respondents rate their emotional state
over the previous week on a four-point (0–3) scale.
Possible scores for each subscale range from 0 to 21
and can be categorised as normal (0–7), mild
(8–10), moderate (11–14) or severe (15–21). The
subscales of the English version of the HADS have
good internal consistency (Cronbach’s alphas ran-
ging from 0.72 to 0.93) [39].
Secondary outcome measures
 The Impact of Event Scale-Revised (IES-R) [40] is a
22-item measure of trauma-related symptoms asso-
ciated with specific life events. The instructions have
been tailored for this trial so participants rate how
distressing each ‘difficulty’ has been over the past
week with respect to their ‘heart event which
occurred recently’. Respondents rate each item on a
five-point scale ranging from 0 (‘not at all’) to 4
(‘extremely’). The IES-R yields a total score ranging
from 0 to 88. The IES-R subscales have good in-
ternal consistency (Cronbach’s alphas ranging from
0.79 to 0.91) as well as good test–retest reliability
ranging from 0.51 to 0.94) [40].
 The Metacognitions Questionnaire 30 (MCQ-30)
[41] measures domains of metacognition assessed by
30 items across five subscales, namely (1) positive
beliefs about worry (e.g. “Worrying helps me cope”);
(2) negative beliefs about thoughts concerning
uncontrollability and danger (e.g. “When I start
worrying I cannot stop”); (3) low cognitive confidence
(e.g. “My memory can mislead me at times”); (4)
beliefs about the need to control thoughts (e.g. “Not
being able to control my thoughts is a sign of
weakness”), and (5) cognitive self-consciousness
(e.g. “I pay close attention to the way my mind
works”). Respondents rate how much they “generally
agree” with the statements presented on a four-point
scale (1 = do not agree; 2 = agree slightly; 3 = agree
moderately; 4 = agree very much). The MCQ-30 also
yields a total score ranging from 30 to 120. The
MCQ-30 total score and the ‘negative beliefs about
thoughts concerning uncontrollability and danger’
subscale will be used in the trial, while recognising the
overlap between these. The total score has been
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selected as the MCQ-30 has been shown to have
a bifactor structure, consisting of a dominant gen-
eral factor alongside the five sub-scales [42]. The
uncontrollability and danger subscale has been se-
lected as it is the primary mechanism targeted in
MCT. These two scales will also be used in medi-
ator and moderator analyses. The MCQ-30 pos-
sesses good internal consistency (Cronbach’s
alphas 0.72 to 0.93 for individual subscales) [41]
as well as good convergent validity and acceptable
test–retest reliability [38, 41, 43].
 The EQ-5D-5L [44] is a widely-used, standardised,
generic measure of HRQoL that assesses an individ-
ual’s health across five dimensions, namely mobility,
self-care, usual activities, pain/discomfort, and anx-
iety/depression. Each dimension has five response cat-
egories ranging in severity from “no problems” to
“extreme problems”. The EQ-5D-5L is a valid and reli-
able measure in the cardiovascular population [45].
Process measure
 The Cognitive Attentional Syndrome-1r (CAS-1r)
has been adapted from the original 16-item version
of the CAS-1 [28] for this study. The CAS-1r
assesses individuals’ metacognitive strategies and
knowledge. The first six items evaluate the extent to
which an individual engages in worry, rumination
and other strategies (e.g. “How much time in the last
week have you found yourself dwelling on or worry-
ing about your problems?”). The final four items
assess an individual’s metacognitive beliefs. The
CAS-1r is scored on a scale from 0 (none of the
time) to 100 (all of the time), with higher scores
indicating more use of metacognitive strategies or
greater conviction in metacognitive beliefs. The
original CAS-1 has adequate internal consistency
(Cronbach’s alpha = 0.86) [42]. The CAS-1r will be
used for mediator and moderator analyses.
Sociodemographic and clinical data questionnaire
 A questionnaire will be used to collect
sociodemographic information (age, sex, ethnic
origin, marital status, living arrangements,
employment status, educational attainment) and
clinical data (height, weight, smoking status, alcohol
use, age at first cardiovascular event, history of
cardiovascular events, comorbidities, past and
current medications for anxiety or depression, past
or current psychological therapies).
Health economic measures
 The primary measure of health benefit is quality-
adjusted life years (QALYs), which will be estimated
from the EQ-5D-5L (see above [44]) and published
utility tariffs [46–48]. The EQ-5D-5L is the measure
recommended by the UK National Institute of
Health and Care Excellence for use in economic
evaluations of new interventions [49]. At the end of
the trial, a data request will be submitted to NHS
Digital to obtain data on hospital-based service use
and the use of mental health services covering all
assessment points (baseline, 4-month and 12-month
follow-up). To supplement these data, an Economic
Patient Questionnaire will assess participants’ use of
inpatient and outpatient services and data on non-
hospital-based health and social care use at all as-
sessment points.
Qualitative methods
The perspectives of both the therapists delivering
Group-MCT and participants in the trial will be evalu-
ated. All therapists will be interviewed longitudinally. In-
terviews conducted before training in Group-MCT will
explore their understanding of the psychological needs
of CR patients and of whether and how CR addresses
these needs. During training, therapists will be prompted
about their understanding of Group-MCT, their experi-
ences of training and their expectations of delivering
Group-MCT. After therapists have completed training
and delivered Group-MCT, they will be prompted about
their experiences of delivering it and about whether and
how their knowledge and understanding of Group-MCT
has altered.
Participants assigned to the intervention group will
be sampled purposively to include ranges of age, psy-
chological distress and diagnoses; sampling will stop
when theoretical saturation is reached [50, 51]. Based
on previous research, it is anticipated that approxi-
mately 30 participants in the intervention group will be
interviewed. Interviews before Group-MCT will explore
participants’ emotional needs and experiences since
their index event, any interaction of emotional needs
with clinical care, and their reactions and expectations
upon being offered Group-MCT. Participants who
complete Group-MCT will then be interviewed about
their experience of the intervention, including its con-
tent and delivery, and any relevance of the intervention
to their emotional distress. Any participants who do
not complete Group-MCT will be asked for interviews
to explore their experience of the intervention and their
reasons for not completing it.
As a check on whether, and how, being offered the
intervention has influenced participants’ accounts,
participants assigned to the control group will also be
interviewed, purposively sampled to include ranges of
age, psychological distress and diagnoses; it is antici-
pated that approximately 10 participants will be inter-
viewed. They will be interviewed only once, will have
Wells et al. Trials  (2018) 19:215 Page 7 of 12
varying exposures to CR, and will be prompted to talk
about their emotional experiences since the index event
and any interaction of emotional needs with clinical
care. Patients who declined to participate but who con-
sent to qualitative interviews will also be invited for an
interview, and will explore their reasons for declining.
Interviews with therapists and participants will be
semi-structured and conversational in style, using an
interview guide. They will be on NHS premises or in
the case of participants in their homes, as participants
wish. Interviews will be anonymously transcribed ver-
batim for analysis.
Outcomes
The primary outcome of the trial is severity of anxiety and
depressive symptoms at 4-month follow-up as measured
by the HADS total score. Secondary outcomes include se-
verity of anxiety and depressive symptoms at 12-month
follow-up, and HRQoL, severity of post-traumatic stress
symptoms and conviction in metacognitive beliefs at both
4- and 12-month follow-up.
Sample size calculation
The trial is designed with 90% power to detect a stan-
dardised mean difference (SMD) between trial arms of 0.
4 in HADS total score at 4-month follow-up. The target
SMD of 0.4 is in the middle of the range of effect sizes
reported for other forms of psychological interventions
for depression [17] and is conservative.
An internal pilot trial with 52 participants was con-
ducted first to ascertain the feasibility of recruitment to
the trial and to collect data on which to calculate a defini-
tive sample size calculation for the main trial. The internal
pilot was assessed at 4-month follow-up. Relative to the
standard deviation in HADS total score at baseline, the
target SMD of 0.4 represents a difference between trial
arms of 2.2 points on the HADS total score. Based on an
observed 35% attrition rate at 4 months (participants not
returning questionnaires), a correlation between HADS
total score at baseline and follow-up of 0.5, an average
group size of three and assumed intracluster correlation
coefficient of 0.05, a total of 332 participants will need to
be recruited, including the 52 already recruited to the pilot
trial as no substantial changes were made to the proce-
dures or trial instruments following the pilot.
Analyses
The trial will be analysed using quantitative, qualitative
and economic methods.
Quantitative analysis
All analyses will follow intention-to-treat principles and a
pre-specified plan. Analysis will be undertaken using Stata
version 14 [52] and an alpha level of 5%. Analysis of
covariance within a regression framework will examine
differences in outcomes between trial arms. The primary
analysis will use the baseline values of each outcome, the
minimisation variables (hospital site, sex, HADS anxiety
and depression scores), and other pre-specified variables
predictive of outcomes as covariates. The analysis will
account for the clustering of patients within CR or CR
plus Group-MCT groups. Appropriate sensitivity analyses
will be conducted to assess the robustness of the results to
missing data (e.g. using multiple imputation methods),
non-normal outcome distributions and choice of
covariates.
If a significant intervention effect on the primary out-
come (HADS total score at 4 months) is detected, a
structural equation modelling framework will be used to
explore whether this effect was mediated by changes in
metacognitions (the basic assumption of the Group-
MCT intervention).
Qualitative analysis
The data from participants and therapists will be ana-
lysed separately. Each analysis will draw upon a pluralist
qualitative approach, initially informed by constant com-
parison and grounded theory principles, to explore what
is present and what is noticeably absent in the data [51].
We will go beyond line-by-line coding of content, to
attend to how participants talked, and to consider data
in the context of the whole interview, successive inter-
views for each participant, the participants’ clinical and
institutional context, and the emerging analysis. Know-
ledge of each participant’s primary outcome (HADS) will
be part of the context for interpreting their accounts.
Data will be considered descriptively at first, with a more
interpretative approach developing as analysis proceeds.
Procedurally, analysis will draw on constant comparison,
as we iterate between the developing analysis and new
interviews and revisit earlier interviews in light of the
developing analysis.
Analysis will be developed and tested by discussion
amongst a core analytic team consisting of a sociologist
and clinical psychologists with experience of qualitative
methods and expertise in MCT, who will read all tran-
scripts, and by periodic discussion in the broader study
team who will read selected transcripts. Differences of
interpretation during discussions will alert the team to
potential competing explanations. Deviant cases will be
highlighted to test and develop the analysis. As well as
consensus validity [53], the emerging analysis will be
judged according to its ‘catalytic validity’ [54], whereby it
should have potential real-life implications, and theoret-
ical validity, whereby it should have implications for
existing theory [54]. Metacognitive theory [23, 24] will
not be imposed as a structure for analysis, but findings
will be related to it.
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Economic analysis
The primary cost effectiveness analysis will use an
intention-to-treat approach to estimate total costs and
QALYs for the 4-month follow-up period of the trial
from the perspective of the NHS and Social Care. The
key outcome of the economic evaluation will be the
incremental cost effectiveness ratio, a joint measure of
cost and health benefit. Each item of resource use will
be multiplied by the relevant published national unit
cost for that item. National unit costs are published an-
nually by the Department of Health [55] and the
Personal Social Services Research Unit, University of
Kent [56]; the price year will be the most recent year for
which national unit costs are available (expected to be
2017/2018). QALYs gained from baseline to follow-up
will be estimated from the EQ-5D-5L and published util-
ity tariffs [46–48].
All missing cost and utility data will be treated as
missing at random and multiple imputations will be
used to impute values for missing data for each follow-
up period. The imputation procedure will use predictive
mean matching and sequential chained equations. The
variables included in the imputation models will be
selected on the basis of descriptive and regression ana-
lyses of the pooled baseline and follow-up data to iden-
tify potential predictors of the utility, follow-up and cost
measures [57]. Cost data will be imputed by category
rather than as a total so that all available data are used
to inform the imputed values.
Regression analysis will be used to estimate the net costs
and net QALYs of Group-MCT plus usual CR compared to
usual CR alone. The regression models will include covari-
ates that may affect the costs or QALYs. The covariates will
be derived from discussion with the trial team and analysis
of the trial data, which will identify variables for inclusion
in a model via a stepwise approach. The net cost and QALY
estimates will be bootstrapped to generate 10,000 pairs of
net costs and QALYs. These will then be used to estimate
the probability that the trial intervention is cost-effective.
Cost-effectiveness planes and cost-effectiveness acceptabil-
ity curves will be plotted. Net benefit statistics will be esti-
mated; these approaches require that net QALYs are
revalued using a monetary value that reflects decision-
makers willingness to pay to gain one QALY. The range of
£0 to £30 k will be used in line with current estimates of
the willingness-to-pay threshold implicit in National Insti-
tute of Health and Care Excellence decisions [58–63].
Sensitivity analyses will explore uncertainty, including
the impact of using alternative sources for costs and util-
ity tariffs, approaches to missing data, key outcomes and
time horizons.
The economic evaluation will be reported in line with
the Consolidated Health Economic Evaluation Reporting
Standards statement [64].
Trial management and oversight arrangements
This trial forms part of a larger research programme
funded by the National Institute of Health Research
under its Programme Grants for Applied Research
scheme (RP-PG-1211 20,011). The programme is over-
seen by an independent programme steering committee,
which meets every 6 months to provide expert advice,
supervise the overall programme on behalf of the
National Institute of Health Research and the sponsor,
and monitor progress against agreed milestones. A
programme executive committee, comprising the chief
investigator, co-investigators, the core project team and
other relevant parties, meets quarterly. Notwithstanding
the legal obligations of the sponsor and chief investiga-
tor, the executive committee has operational responsibil-
ity for the conduct of the trial, including monitoring
overall progress to ensure adherence to the protocol and
for taking appropriate action to safeguard participants
and the quality of the trial. A programme management
group comprising the chief investigator and core project
team meet weekly to oversee the day-to-day manage-
ment of the programme. There is also a service user
advisory group, which meets at least every 6 months and
provides advice and feedback on a range of trial-related
activities, e.g. reviewing study documents.
MAHSC-CTU is a clinical trials unit with UK Clinical
Research Collaboration registration, which provides full
data management and trial monitoring services for the
trial as well as having an advisory role with regards to
trial conduct and adherence to regulatory requirements.
Safety reporting
Health professionals delivering the Group-MCT inter-
vention will monitor participants attending the group
sessions for any potential adverse events or serious
adverse events. Any events deemed to be related to the
intervention will be reported to the research team and
reviewed by a designated sub-investigator who is not
blind to treatment allocation. Any serious adverse events
will be reported to the ethics committee, the programme
steering committee and the sponsor’s Research and
Innovation Manager within 7 days of the event. Adverse
events and serious adverse events will be reviewed on a
quarterly basis at the programme’s executive committee
meetings.
Dissemination
The trial results will be published in peer-reviewed
journals and these will be made freely available and
online wherever possible. The findings will also be pre-
sented at national and international clinical-academic
cardiovascular, health economic and psychological ther-
apies conferences as well as general public health con-
ferences, regional conferences and forums, and public
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involvement events. Important protocol modifications
will be communicated to the research ethics committee,
trial registry, clinical trials unit, steering committee and
all relevant parties.
Discussion
Anxiety and depression are common among patients with
heart disease, with 37% reporting significant anxiety and/
or depressive symptoms [1]. Currently available drug and
psychological treatments have only small effects on dis-
tress and quality of life, and no benefits to physical health
in this patient population [17–22]. Furthermore, the needs
of heart disease patients are not being met currently
within UK NHS CR services. Given the limitations of
existing CR services and treatment options, there is an
urgent need for new, effective psychological interventions
for depression and anxiety to be integrated into the CR
pathway in order to improve clinical outcomes. MCT [28]
has been empirically tested in mental health settings
through case series and uncontrolled and controlled trials
[29–36], where it has consistently demonstrated large
post-treatment reductions in depression and anxiety and
high recovery rates. The PATHWAY Group-MCT trial
will establish the effectiveness of Group-MCT in alleviat-
ing anxiety and depression in CR patients. The study also
will provide quantitative data for modelling the psycho-
logical mechanisms of therapeutic change and qualitative
data to understand barriers and enablers to the trial and
to the intervention, and participants’ and therapists’ expe-
riences of MCT. Finally, to aid decision-making, data on
healthcare service use and health status will be used to
assess whether Group-MCT is a potentially cost-effective
intervention.
Trial status
The PATHWAY Group-MCT trial is currently recruiting
participants and recruitment is predicted to continue
until February 2018.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Intervention Trials (SPIRIT) Checklist. (DOC 121 kb)
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